OBJECTIVE: We evaluated the relationship between annually measured serum endogenous estradiol and the development or worsening of stress and urge incontinence symptoms during a period of 8 years in women transitioning through menopause. METHODS: This is a longitudinal analysis of women with incontinence in the Study of Women's Health Across the Nation, a multicenter, multiracial/ethnic prospective cohort study of community-dwelling women transitioning through menopause. At baseline and at each of the eight annual visits, the Study of Women's Health Across the Nation elicited the frequency and type of incontinence using a self-administered questionnaire and drew a blood sample on days 2 to 5 of the menstrual cycle. All endocrine assays were performed using a double-antibody chemiluminescent immunoassay. We analyzed the data using discrete Cox survival models and generalized estimating equations with time-dependent covariates. RESULTS: Estradiol levels drawn at either the annual visit concurrent with or previous to the first report of incontinence were not associated with the development of any (hazard ratio, 0.99; 95% CI, 0.99-1.01), stress, or urge incontinence in previously continent women. Similarly, estradiol levels were not associated with the worsening of any (odds ratio, 1.00; 95% CI, 0.99-1.01), stress, or urge incontinence in incontinent women. The change in estradiol levels from one year to the next was also not associated with the development (hazard ratio, 0.98; 95% CI, 0.97-1.00) or worsening (odds ratio, 1.03; 95% CI, 0.99-1.05) of incontinence. CONCLUSIONS: We found that annually measured values and year-to-year changes in endogenous estradiol levels had no effect on the development or worsening of incontinence in women transitioning through menopause.
OBJECTIVE: We evaluated the relationship between annually measured serum endogenous estradiol and the development or worsening of stress and urge incontinence symptoms during a period of 8 years in women transitioning through menopause. METHODS: This is a longitudinal analysis of women with incontinence in the Study of Women's Health Across the Nation, a multicenter, multiracial/ethnic prospective cohort study of community-dwelling women transitioning through menopause. At baseline and at each of the eight annual visits, the Study of Women's Health Across the Nation elicited the frequency and type of incontinence using a self-administered questionnaire and drew a blood sample on days 2 to 5 of the menstrual cycle. All endocrine assays were performed using a double-antibody chemiluminescent immunoassay. We analyzed the data using discrete Cox survival models and generalized estimating equations with time-dependent covariates. RESULTS:Estradiol levels drawn at either the annual visit concurrent with or previous to the first report of incontinence were not associated with the development of any (hazard ratio, 0.99; 95% CI, 0.99-1.01), stress, or urge incontinence in previously continent women. Similarly, estradiol levels were not associated with the worsening of any (odds ratio, 1.00; 95% CI, 0.99-1.01), stress, or urge incontinence in incontinent women. The change in estradiol levels from one year to the next was also not associated with the development (hazard ratio, 0.98; 95% CI, 0.97-1.00) or worsening (odds ratio, 1.03; 95% CI, 0.99-1.05) of incontinence. CONCLUSIONS: We found that annually measured values and year-to-year changes in endogenous estradiol levels had no effect on the development or worsening of incontinence in women transitioning through menopause.
Authors: Z I Jármy-Di Bella; M J Girão; M F Sartori; V Di Bella Júnior; H M Lederman; E C Baracat; G R Lima Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2000-06
Authors: Barry G England; George H Parsons; Russell M Possley; Daniel S McConnell; A Rees Midgley Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: J B Gebhart; D J Rickard; T J Barrett; T G Lesnick; M J Webb; K C Podratz; T C Spelsberg Journal: Am J Obstet Gynecol Date: 2001-12 Impact factor: 8.661
Authors: L Elaine Waetjen; Jingjing Ye; Wen-Ying Feng; Wesley O Johnson; Gail A Greendale; Carolyn M Sampselle; Barbara Sternfield; Siobàn D Harlow; Ellen B Gold Journal: Obstet Gynecol Date: 2009-11 Impact factor: 7.661
Authors: R A Jackson; E Vittinghoff; A M Kanaya; T P Miles; H E Resnick; S B Kritchevsky; E M Simonsick; J S Brown Journal: Obstet Gynecol Date: 2004-08 Impact factor: 7.661
Authors: Elizabeth A Jackson; Samar R El Khoudary; Sybil L Crawford; Karen Matthews; Hadine Joffe; Claudia Chae; Rebecca C Thurston Journal: J Womens Health (Larchmt) Date: 2016-07-12 Impact factor: 2.681
Authors: Ellen B Gold; Sybil L Crawford; Janie F Shelton; Ping G Tepper; Carolyn J Crandall; Gail A Greendale; Karen A Matthews; Rebecca C Thurston; Nancy E Avis Journal: Menopause Date: 2017-01 Impact factor: 2.953
Authors: Luiz Gustavo Oliveira Brito; Luciane Maria Oliveira Brito; Maria Bethânia da Costa Chein; Elizabeth Santos de Andrade Malheiros; Thaiana Bezerra Duarte; Aarão Mendes Pinto-Neto Journal: Int Urogynecol J Date: 2012-03-13 Impact factor: 2.894
Authors: Ellen B Gold; Guibo Xing; Nancy E Avis; Sioban Harlow; Hadine Joffe; Karen Matthews; Jelena M Pavlovic; Rebecca C Thurston; Elaine Waetjen Journal: Menopause Date: 2022-08-01 Impact factor: 3.310
Authors: Samar R El Khoudary; Gail Greendale; Sybil L Crawford; Nancy E Avis; Maria M Brooks; Rebecca C Thurston; Carrie Karvonen-Gutierrez; L Elaine Waetjen; Karen Matthews Journal: Menopause Date: 2019-10 Impact factor: 2.953